Vera Therapeutics Provides Business Update and Reports Third Quarter Financial ResultsGlobeNewsWire • 11/09/23
Vera Therapeutics Presents Positive Data from Phase 2b ORIGIN Study Showing Resolution of Hematuria in Majority of Patients at the American Society of Nephrology Kidney Week 2023GlobeNewsWire • 11/04/23
Down -34.74% in 4 Weeks, Here's Why You Should You Buy the Dip in Vera Therapeutics, Inc. (VERA)Zacks Investment Research • 10/18/23
Down -38.05% in 4 Weeks, Here's Why You Should You Buy the Dip in Vera Therapeutics, Inc. (VERA)Zacks Investment Research • 10/17/23
Down -37.74% in 4 Weeks, Here's Why Vera Therapeutics, Inc. (VERA) Looks Ripe for a TurnaroundZacks Investment Research • 10/16/23
Vera Therapeutics to Present Three Posters at the American Society of Nephrology Kidney Week 2023 Annual MeetingGlobeNewsWire • 10/13/23
Vera Therapeutics Provides Business Update and Reports Second Quarter Financial ResultsGlobeNewsWire • 08/10/23
Vera Therapeutics Announces Positive Week 36 Efficacy and Safety Results of Phase 2b ORIGIN Clinical Trial of Atacicept in IgAN in Late-Breaking Presentation at 60th European Renal Association (ERA) CongressGlobeNewsWire • 06/17/23
Vera Therapeutics to Host Presentation of Week 36 Data from Phase 2b ORIGIN Clinical Trial of Atacicept in IgANGlobeNewsWire • 06/15/23
Novartis deal for Chinook makes kidney-treatment competitors more attractive, analysts sayMarket Watch • 06/12/23
Vera Therapeutics to Participate in the 44th Annual Goldman Sachs Global Healthcare ConferenceGlobeNewsWire • 06/08/23
Vera Therapeutics Initiates Pivotal Phase 3 (ORIGIN 3) Clinical Trial of Atacicept for the Treatment of IgA Nephropathy (IgAN)GlobeNewsWire • 06/07/23
Vera Therapeutics Provides Business Update and Reports First Quarter Financial ResultsGlobeNewsWire • 05/11/23